Aarti Pharmalabs Limited

Aarti Pharmalabs is a pharmaceutical manufacturer producing APIs, pharmaceutical intermediates, and xanthine derivatives for Indian and international markets. APIs serve multiple therapeutic areas, while intermediates and xanthine products, including caffeine and theophylline, support chemical and formulation demand. Contract development and manufacturing services add project-based drug-substance revenue. Q1 FY27 results were published, but revenue declined 14% year-on-year and profit fell 35.9%, limiting evidence of near-term growth acceleration. Improving margins indicate operating recovery despite weaker sales and earnings, but ROE is unavailable for quality assessment. Debt/equity of 37.36 implies extreme leverage, which can materially distort and pressure shareholder returns through financing costs. At 35.6 times earnings, the shares appear rich versus current contraction, trading at a premium to negative growth. The outlook remains neutral, with valuation dependent on API demand recovery, contract manufacturing execution, and leverage reduction.